Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2017 · 10-Q
Revenue$413.60K$413.60K−31.0% vs Q3 2016 Net Income-$9.33M-$9.33MN/M vs Q3 2016 EPS Diluted-$0.54-$0.54N/M vs Q3 2016 Operating Income-$9,409,452N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,095,705N/M Margins · derivedOperating margin-2275.0%−483.0 pt vs Q3 2016
Net margin-2256.3%−480.7 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 6, 2017 · 37 d after period end